Skip to main content

01.02.2010

Renal Sympathetic Nerve Ablation: The New Frontier in the Treatment of Hypertension

verfasst von: Markus P. Schlaich, Henry Krum, Paul A. Sobotka

Erschienen in: Current Hypertension Reports | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

The sympathetic nervous system plays an important role in circulatory and metabolic control and has clearly been established as a major contributor to the development of hypertension, as elevated sympathetic nerve activity initiates and sustains the elevation of blood pressure. Increased sympathetic outflow to the heart, resulting in increased cardiac output and neurally mediated vasoconstriction of peripheral blood vessels, is an obvious example of a neural pathophysiologic pathway leading to elevated blood pressure. The consequences of increased sympathetic outflow to the kidneys, perhaps most important in this context, are sodium and water retention, increased renin release, and alterations of renal blood flow—effects that contribute substantially to both acute and long-term blood pressure elevations. Accordingly, renal sympathetic nerve ablation appears to be a logical therapeutic approach for the treatment of hypertension. Recent reports on a novel catheter-based renal nerve ablation procedure reviewed in this article are promising.
Literatur
1.
Zurück zum Zitat Perkovic V, Huxley R, Wu Y, et al.: The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007, 50(6):991–997.CrossRefPubMed Perkovic V, Huxley R, Wu Y, et al.: The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007, 50(6):991–997.CrossRefPubMed
2.
Zurück zum Zitat Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455):217–223.PubMed Kearney PM, Whelton M, Reynolds K, et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365(9455):217–223.PubMed
3.
Zurück zum Zitat DiBona GF: The sympathetic nervous system and hypertension: recent developments. Hypertension 2004, 43(2):147–150.CrossRefPubMed DiBona GF: The sympathetic nervous system and hypertension: recent developments. Hypertension 2004, 43(2):147–150.CrossRefPubMed
4.
Zurück zum Zitat DiBona GF, Kopp UC: Neural control of renal function. Physiol Rev 1997, 77(1):75–197.PubMed DiBona GF, Kopp UC: Neural control of renal function. Physiol Rev 1997, 77(1):75–197.PubMed
5.
Zurück zum Zitat Alexander BT, Hendon AE, Ferril G, Dwyer TM: Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion. Hypertension 2005, 45(4):754–758.CrossRefPubMed Alexander BT, Hendon AE, Ferril G, Dwyer TM: Renal denervation abolishes hypertension in low-birth-weight offspring from pregnant rats with reduced uterine perfusion. Hypertension 2005, 45(4):754–758.CrossRefPubMed
6.
Zurück zum Zitat Kassab S, Kato T, Wilkins FC, et al.: Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25(4 Pt 2):893–897.PubMed Kassab S, Kato T, Wilkins FC, et al.: Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension 1995, 25(4 Pt 2):893–897.PubMed
7.
Zurück zum Zitat Smithwick RH, Thompson JE: Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953, 152(16):1501–1504.PubMed Smithwick RH, Thompson JE: Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc 1953, 152(16):1501–1504.PubMed
8.
Zurück zum Zitat Morrissey DM, Brookes VS, Cooke WT: Sympathectomy in the treatment of hypertension, review of 122 cases. Lancet 1953, 1(6757):403–408.CrossRefPubMed Morrissey DM, Brookes VS, Cooke WT: Sympathectomy in the treatment of hypertension, review of 122 cases. Lancet 1953, 1(6757):403–408.CrossRefPubMed
9.
Zurück zum Zitat Esler M, Jennings G, Biviano B, et al.: Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1986, 8(Suppl 5):S39–S43.CrossRefPubMed Esler M, Jennings G, Biviano B, et al.: Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol 1986, 8(Suppl 5):S39–S43.CrossRefPubMed
10.
Zurück zum Zitat Schlaich MP, Lambert E, Kaye DM, et al.: Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004, 43(2):169–175.CrossRefPubMed Schlaich MP, Lambert E, Kaye DM, et al.: Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension 2004, 43(2):169–175.CrossRefPubMed
11.
Zurück zum Zitat Esler M, Jennings G, Lambert G: Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989, 2(3 Pt 2):140 S–146 S.PubMed Esler M, Jennings G, Lambert G: Noradrenaline release and the pathophysiology of primary human hypertension. Am J Hypertens 1989, 2(3 Pt 2):140 S–146 S.PubMed
12.
Zurück zum Zitat Hasking GJ, Esler MD, Jennings GL, et al.: Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986, 73(4):615–621.PubMed Hasking GJ, Esler MD, Jennings GL, et al.: Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986, 73(4):615–621.PubMed
13.
Zurück zum Zitat Aggarwal A, Esler MD, Morris MJ, et al.: Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension 2003, 41(3):553–557.CrossRefPubMed Aggarwal A, Esler MD, Morris MJ, et al.: Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension 2003, 41(3):553–557.CrossRefPubMed
14.
Zurück zum Zitat Petersson M, Friberg P, Eisenhofer G, et al.: Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005, 26(9):906–913.CrossRefPubMed Petersson M, Friberg P, Eisenhofer G, et al.: Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure. Eur Heart J 2005, 26(9):906–913.CrossRefPubMed
15.
Zurück zum Zitat Barajas L: Innervation of the renal cortex. Fed Proc 1978, 37(5):1192–1201.PubMed Barajas L: Innervation of the renal cortex. Fed Proc 1978, 37(5):1192–1201.PubMed
16.
Zurück zum Zitat Bell-Reuss E, Trevino DL, Gottschalk CW: Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest 1976, 57(4):1104–1107.CrossRefPubMed Bell-Reuss E, Trevino DL, Gottschalk CW: Effect of renal sympathetic nerve stimulation on proximal water and sodium reabsorption. J Clin Invest 1976, 57(4):1104–1107.CrossRefPubMed
17.
Zurück zum Zitat Kirchheim H, Ehmke H, Persson P: Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 1989, 67(17):858–864.CrossRefPubMed Kirchheim H, Ehmke H, Persson P: Sympathetic modulation of renal hemodynamics, renin release and sodium excretion. Klin Wochenschr 1989, 67(17):858–864.CrossRefPubMed
18.
Zurück zum Zitat Kon V: Neural control of renal circulation. Miner Electrolyte Metab 1989, 15(1–2):33–43.PubMed Kon V: Neural control of renal circulation. Miner Electrolyte Metab 1989, 15(1–2):33–43.PubMed
19.
Zurück zum Zitat Zanchetti AS: Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 1977, 56(5):691–698.PubMed Zanchetti AS: Neural regulation of renin release: experimental evidence and clinical implications in arterial hypertension. Circulation 1977, 56(5):691–698.PubMed
20.
Zurück zum Zitat Campese VM: Neurogenic factors and hypertension in chronic renal failure. J Nephrol 1997, 10(4):184–187.PubMed Campese VM: Neurogenic factors and hypertension in chronic renal failure. J Nephrol 1997, 10(4):184–187.PubMed
21.
Zurück zum Zitat Ye S, Gamburd M, Mozayeni P, et al.: A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998, 11(6 Pt 1):723–728.CrossRefPubMed Ye S, Gamburd M, Mozayeni P, et al.: A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998, 11(6 Pt 1):723–728.CrossRefPubMed
22.
Zurück zum Zitat Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002, 15(8):717–724.CrossRefPubMed Ye S, Zhong H, Yanamadala V, Campese VM: Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002, 15(8):717–724.CrossRefPubMed
23.
Zurück zum Zitat Campese VM: Neurogenic factors and hypertension in renal disease. Kidney Int 2000, 57(Suppl 75):S2–S6.CrossRef Campese VM: Neurogenic factors and hypertension in renal disease. Kidney Int 2000, 57(Suppl 75):S2–S6.CrossRef
24.
Zurück zum Zitat Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25(4 Pt 2):878–882.PubMed Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995, 25(4 Pt 2):878–882.PubMed
25.
Zurück zum Zitat Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995, 26(5):861–865.CrossRefPubMed Campese VM, Kogosov E, Koss M: Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995, 26(5):861–865.CrossRefPubMed
26.
Zurück zum Zitat DiBona GF: Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002, 11(2):197–200.CrossRefPubMed DiBona GF: Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002, 11(2):197–200.CrossRefPubMed
27.
Zurück zum Zitat DiBona GF: Neural control of the kidney: past, present, and future. Hypertension 2003, 41(3 Pt 2):621–624.CrossRefPubMed DiBona GF: Neural control of the kidney: past, present, and future. Hypertension 2003, 41(3 Pt 2):621–624.CrossRefPubMed
28.
Zurück zum Zitat Fajardo J, Lopez-Novoa JM: Effect of chemical sympathectomy on renal hydroelectrolytic handling in dogs with chronic caval constriction. Clin Physiol Biochem 1986, 4(4):252–256.PubMed Fajardo J, Lopez-Novoa JM: Effect of chemical sympathectomy on renal hydroelectrolytic handling in dogs with chronic caval constriction. Clin Physiol Biochem 1986, 4(4):252–256.PubMed
29.
Zurück zum Zitat Norman RA Jr, Murphy WR, Dzielak DJ, et al.: Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension 1984, 6(5):622–626.PubMed Norman RA Jr, Murphy WR, Dzielak DJ, et al.: Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension 1984, 6(5):622–626.PubMed
30.
Zurück zum Zitat Joles JA, Koomans HA: Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004, 43(4):699–706.CrossRefPubMed Joles JA, Koomans HA: Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004, 43(4):699–706.CrossRefPubMed
31.
Zurück zum Zitat Mailloux LU, Haley WE: Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998, 32(5):705–719.CrossRefPubMed Mailloux LU, Haley WE: Hypertension in the ESRD patient: pathophysiology, therapy, outcomes, and future directions. Am J Kidney Dis 1998, 32(5):705–719.CrossRefPubMed
32.
Zurück zum Zitat Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34(5):795–808.CrossRefPubMed Ritz E, Rychlik I, Locatelli F, Halimi S: End-stage renal failure in type 2 diabetes: a medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999, 34(5):795–808.CrossRefPubMed
33.
Zurück zum Zitat Klag MJ, Whelton PK, Randall BL, et al.: Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334(1):13–18.CrossRefPubMed Klag MJ, Whelton PK, Randall BL, et al.: Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334(1):13–18.CrossRefPubMed
34.
Zurück zum Zitat Rostand SG, Brunzell JD, Cannon RO 3rd, Victor RG: Cardiovascular complications in renal failure. J Am Soc Nephrol 1991, 2(6):1053–1062.PubMed Rostand SG, Brunzell JD, Cannon RO 3rd, Victor RG: Cardiovascular complications in renal failure. J Am Soc Nephrol 1991, 2(6):1053–1062.PubMed
35.
Zurück zum Zitat Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339(12):799–805.CrossRefPubMed Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339(12):799–805.CrossRefPubMed
36.
Zurück zum Zitat Coresh J, Wei GL, McQuillan G, et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2001, 161(9):1207–1216.CrossRefPubMed Coresh J, Wei GL, McQuillan G, et al.: Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 2001, 161(9):1207–1216.CrossRefPubMed
37.
Zurück zum Zitat Tonelli M, Bohm C, Pandeya S, et al.: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001, 37(3):484–489.CrossRefPubMed Tonelli M, Bohm C, Pandeya S, et al.: Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. Am J Kidney Dis 2001, 37(3):484–489.CrossRefPubMed
38.
Zurück zum Zitat Lazarus JM, Hampers C, Merrill JP: Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy. Arch Intern Med 1974, 133(6):1059–1066.CrossRefPubMed Lazarus JM, Hampers C, Merrill JP: Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy. Arch Intern Med 1974, 133(6):1059–1066.CrossRefPubMed
39.
Zurück zum Zitat Ligtenberg G, Blankestijn PJ, Oey PL, et al.: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999, 340(17):1321–1328.CrossRefPubMed Ligtenberg G, Blankestijn PJ, Oey PL, et al.: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999, 340(17):1321–1328.CrossRefPubMed
40.
Zurück zum Zitat Grassi G, Seravalle G, Colombo M, et al.: Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998, 97(20):2037–2042.PubMed Grassi G, Seravalle G, Colombo M, et al.: Body weight reduction, sympathetic nerve traffic, and arterial baroreflex in obese normotensive humans. Circulation 1998, 97(20):2037–2042.PubMed
41.
Zurück zum Zitat Narkiewicz K, Pesek CA, Kato M, et al.: Baroreflex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. Hypertension 1998, 32(6):1039–1043.PubMed Narkiewicz K, Pesek CA, Kato M, et al.: Baroreflex control of sympathetic nerve activity and heart rate in obstructive sleep apnea. Hypertension 1998, 32(6):1039–1043.PubMed
42.
Zurück zum Zitat Schobel HP, Fischer T, Heuszer K, et al.: Preeclampsia—a state of sympathetic overactivity. N Engl J Med 1996, 335(20):1480–1485.CrossRefPubMed Schobel HP, Fischer T, Heuszer K, et al.: Preeclampsia—a state of sympathetic overactivity. N Engl J Med 1996, 335(20):1480–1485.CrossRefPubMed
43.
Zurück zum Zitat Zoccali C, Mallamaci F, Parlongo S, et al.: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002, 105(11):1354–1359.CrossRefPubMed Zoccali C, Mallamaci F, Parlongo S, et al.: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002, 105(11):1354–1359.CrossRefPubMed
44.
Zurück zum Zitat Vonend O, Marsalek P, Russ H, et al.: Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003, 21(9):1709–1717.CrossRefPubMed Vonend O, Marsalek P, Russ H, et al.: Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens 2003, 21(9):1709–1717.CrossRefPubMed
45.
Zurück zum Zitat Strojek K, Grzeszczak W, Gorska J, et al.: Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001, 12(3):602–605.PubMed Strojek K, Grzeszczak W, Gorska J, et al.: Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? J Am Soc Nephrol 2001, 12(3):602–605.PubMed
46.
Zurück zum Zitat Onesti G, Kim KE, Greco JA, et al.: Blood pressure regulation in end-stage renal disease and anephric man. Circ Res 1975, 36(6 Suppl 1):145–152.PubMed Onesti G, Kim KE, Greco JA, et al.: Blood pressure regulation in end-stage renal disease and anephric man. Circ Res 1975, 36(6 Suppl 1):145–152.PubMed
47.
Zurück zum Zitat Getts RT, Hazlett SM, Sharma SB, et al.: Regression of left ventricular hypertrophy after bilateral nephrectomy. Nephrol Dial Transplant 2006, 21(4):1089–1091.CrossRefPubMed Getts RT, Hazlett SM, Sharma SB, et al.: Regression of left ventricular hypertrophy after bilateral nephrectomy. Nephrol Dial Transplant 2006, 21(4):1089–1091.CrossRefPubMed
48.
Zurück zum Zitat Schlaich MP, Kaye DM, Lambert E, et al.: Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003, 108(5):560–565.CrossRefPubMed Schlaich MP, Kaye DM, Lambert E, et al.: Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 2003, 108(5):560–565.CrossRefPubMed
49.
Zurück zum Zitat •• Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373(9671):1275–1281. This study presents the first data on the safety and efficacy of a novel catheter-based approach to functionally denervate the human kidney, demonstrating a favorable safety profile and substantial and sustained reductions in blood pressure. CrossRefPubMed •• Krum H, Schlaich M, Whitbourn R, et al.: Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373(9671):1275–1281. This study presents the first data on the safety and efficacy of a novel catheter-based approach to functionally denervate the human kidney, demonstrating a favorable safety profile and substantial and sustained reductions in blood pressure. CrossRefPubMed
50.
Zurück zum Zitat •• Schlaich MP, Sobotka PA, Krum H, et al.: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361(9):932–934. This study reports on a patient treated with catheter-based renal nerve ablation, demonstrating a reduction in central sympathetic outflow indicative of a potential involvement of afferent nerve fibers in the sustained blood pressure reduction associated with the procedure. CrossRefPubMed •• Schlaich MP, Sobotka PA, Krum H, et al.: Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361(9):932–934. This study reports on a patient treated with catheter-based renal nerve ablation, demonstrating a reduction in central sympathetic outflow indicative of a potential involvement of afferent nerve fibers in the sustained blood pressure reduction associated with the procedure. CrossRefPubMed
Metadaten
Titel
Renal Sympathetic Nerve Ablation: The New Frontier in the Treatment of Hypertension
verfasst von
Markus P. Schlaich
Henry Krum
Paul A. Sobotka
Publikationsdatum
01.02.2010
Verlag
Current Science Inc.
Erschienen in
Current Hypertension Reports / Ausgabe 1/2010
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-009-0078-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.